Protagonist Therapeutics 报告了银屑病新药 icotrokinra 的成功 3 期结果。 Protagonist Therapeutics reports successful Phase 3 results for new psoriasis drug icotrokinra.
据Protagonist Therapeutics报道,对于ICOTROKINRA,一种用于中度至重度斑块性牛皮的新型口服治疗,已经取得了成功的第三期结果. Protagonist Therapeutics has reported successful Phase 3 results for icotrokinra, a new oral treatment for moderate to severe plaque psoriasis. 在试验中,在16周,64. 7% 的患者获得了显著的皮肤清除,到24周改善到74. 1%. In trials, icotrokinra achieved significant skin clearance in 64.7% of patients at week 16, improving to 74.1% by week 24. 该药物达到了初级疗效端点,并展示了与先前研究一致的安全概况。 The drug met primary efficacy endpoints and showed a safety profile consistent with earlier studies. 主角从强生公司获得了1.65亿美元的里程碑，并有资格获得额外的付款和特许权使用费。 Protagonist earned a $165 million milestone from Johnson & Johnson and is eligible for additional payments and royalties.